登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
ClinicalTrials.gov 上登记的一项鼻咽癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 2
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 牵头方(推断)中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
- 研究中心中国医学科学院肿瘤医院深圳医院Cancer Hospital CAMS – Shenzhen深圳医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07325539,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 65 岁;性别:不限
登记记录的入选字段
Histologically confirmed non-keratinizing nasopharyngeal carcinoma (WHO Type II or III).
入选标准第 2 条
Myocardial ischemia (above Grade I), myocardial infarction, arrhythmia (including QTc ≥480 ms), or ≥ Grade 2 congestive heart failure (NYHA classification) within 6 months prior to enrollment.
排除标准第 12 条
Patients with newly diagnosed metastatic NPC, or patients with locoregionally advanced NPC who developed metastasis ≥6 months or recurrence ≥12 months after completing radical radiotherapy/chemotherapy for the primary lesion.
入选标准第 5 条
Disease progression within 6 months after completing standard treatment for locoregionally advanced nasopharyngeal carcinoma.
排除标准第 1 条
ECOG Performance Status score of 0-1.
入选标准第 3 条
Hemoglobin (Hb) ≥90 g/L.
入选标准第 9 条
White Blood Cell (WBC) count ≥4.0 × 10⁹/L.
入选标准第 10 条
Platelet count (PLT) ≥100 × 10⁹/L.
入选标准第 11 条
Total Bilirubin (TBIL) ≤1.5 × Upper Limit of Normal (ULN).
入选标准第 13 条
Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤2.5 × ULN.
入选标准第 14 条
Serum Creatinine (Cr) ≤1.5 × ULN AND Creatinine Clearance (CCr) ≥60 mL/min.
入选标准第 15 条
Coagulation function: INR and APTT ≤1.5 × ULN.
入选标准第 16 条
Thyroid function: TSH ≤ ULN. If abnormal, FT3 and FT4 levels should be considered; patients can be enrolled if FT3 and FT4 levels are normal.
入选标准第 18 条
At least one measurable lesion as per RECIST v1.1 criteria.
入选标准第 4 条
Diagnosis of other malignancies within 5 years prior to enrollment, except for cured non-melanoma skin cancer, carcinoma in situ of the cervix, and papillary thyroid carcinoma.
排除标准第 14 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07325539,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age: 18-65 years old. Histologically confirmed non-keratinizing nasopharyngeal carcinoma (WHO Type II or III). ECOG Performance Status score of 0-1. At least one measurable lesion as per RECIST v1.1 criteria. Patients with newly diagnosed metastatic NPC, or patients with locoregionally advanced NPC who developed metastasis ≥6 months or recurrence ≥12 months after completing radical radiotherapy/chemotherapy for the primary lesion. No prior radiotherapy, chemotherapy, immunotherapy, or biological therapy for recurrent/metastatic lesions. Adequate organ function, meeting the following criteria within 7 days prior to treatment: Hematological criteria (without transfusion or hematopoietic growth factor support within 14 days): Hemoglobin (Hb) ≥90 g/L. White Blood Cell (WBC) count ≥4.0 × 10⁹/L. Platelet count (PLT) ≥100 × 10⁹/L. Biochemical criteria: Total Bilirubin (TBIL) ≤1.5 × Upper Limit of Normal (ULN). Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤2.5 × ULN. Serum Creatinine (Cr) ≤1.5 × ULN AND Creatinine Clearance (CCr) ≥60 mL/min. Coagulation function: INR and APTT ≤1.5 × ULN. Normal results for myocardial injury markers, heart failure markers, and electrocardiogram (ECG). For patients with abnormal results in any of these, the investigator will assess the need for Doppler echocardiography. Thyroid function: TSH ≤ ULN. If abnormal, FT3 and FT4 levels should be considered; patients can be enrolled if FT3 and FT4 levels are normal. Women of childbearing potential must have used reliable contraception, have a negative serum pregnancy test within 7 days before enrollment, and be willing to use adequate contraception during the trial and for 8 weeks after the last dose of the study drug, or be surgically sterile. Men must agree to use adequate contraception or be surgically sterile during the trial and for 8 weeks after the last dose. Voluntary provision of signed informed consent, with good compliance.排除标准:Exclusion Criteria:
Disease progression within 6 months after completing standard treatment for locoregionally advanced nasopharyngeal carcinoma. Absence of identifiable tumor lesions in both the primary site and locoregional lymph nodes, precluding the development of an LDRT plan. Inability to undergo MRI due to reasons such as implanted metal devices or claustrophobia. Requirement for systemic use of corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to the first dose or during the study. Inhaled or topical steroids and adrenal replacement steroid doses >10 mg/day prednisone equivalent are permitted in the absence of active autoimmune disease. Physiological replacement doses of corticosteroids (≤10 mg/day prednisone equivalent) are allowed. Recurrent target lesions suitable for curative surgery or a second course of radiotherapy. History of any active autoimmune or autoimmune disease, or known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. Exceptions include type I diabetes, hypothyroidism requiring hormone replacement therapy, and skin disorders not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia). Active or uncontrolled severe infection (≥CTCAE Grade 3) within 4 weeks prior to enrollment. History of active tuberculosis within the past year, regardless of treatment. Patients with a history of active pulmonary tuberculosis over 1 year ago who have documented evidence of adequate past anti-tuberculosis treatment may be considered; otherwise, they are excluded. History of hypertension that cannot be adequately controlled with a single antihypertensive medication (systolic BP ≥150 mmHg or diastolic BP ≥90 mmHg). Clinically significant bleeding symptoms or definite bleeding tendency, specifically excluding cases of local recurrence with high bleeding risk or cases within 1 year post-radiotherapy assessed to have a high risk of necrosis. Urinalysis showing urine protein ≥ ++ AND confirmed 24-hour urine protein ≥1.0 g. Myocardial ischemia (above Grade I), myocardial infarction, arrhythmia (including QTc ≥480 ms), or ≥ Grade 2 congestive heart failure (NYHA classification) within 6 months prior to enrollment. If an echocardiogram is required per Inclusion Criterion 7(4), results showing Left Ventricular Ejection Fraction (LVEF) below the lower limit of normal (60%). Diagnosis of other malignancies within 5 years prior to enrollment, except for cured non-melanoma skin cancer, carcinoma in situ of the cervix, and papillary thyroid carcinoma. Presence of leptomeningeal or central nervous system metastases. HIV positive, TP positive, liver cirrhosis, decompensated liver disease, active hepatitis (uncontrolled active hepatitis despite treatment: Hepatitis B - HBsAg positive and HBV DNA ≥1 × 10⁴ copies/mL; Hepatitis C - HCV RNA positive with abnormal liver function; co-infection with HBV and HCV) requiring antiviral therapy. Participation in another anti-tumor drug clinical trial within 4 weeks prior to enrollment. Administration of any live attenuated vaccine within 30 days prior to enrollment. Contraindications to radiotherapy. Known allergy to the study drug or any of its excipients, or history of severe allergic reactions to other monoclonal antibodies. History of psychoactive drug abuse unable to be abstained, or presence of psychiatric disorders. Any other condition assessed by the investigator as potentially endangering the patient's safety or compliance, including severe concurrent diseases (including psychiatric disorders) requiring prompt treatment, severely abnormal laboratory test results, or other psychological, familial, or sociological factors deemed high-risk.
引自 ClinicalTrials.gov, NCT07325539, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07325539,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。